Latest Content

Expert Explains the Side Effects of Ordspono in R/R Follicular Lymphoma

March 14th 2025, 4:00pm

By Dr. Deepa Jagadeesh

Video

Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.

Blue Light Cystoscopy Reduces Recurrence in High-Risk Bladder Cancer

March 14th 2025, 3:00pm

By Ryan Scott

Article

Blue light cystoscopy had a statistically significant reduction in risk of recurrence versus white light cystoscopy in high-risk bladder cancer.

Longer Imbruvica and Venclexta Treatment May Be Beneficial in R/R CLL

March 14th 2025, 1:00pm

By Alex Biese

Article

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found to be beneficial.

What is Late-Line RRMM and How is it Determined?

March 14th 2025, 12:00pm

By Saad Usmani, MD

Video

Panelists discuss how the term "late-line" in relapsed/refractory multiple myeloma typically refers to patients who have progressed through multiple previous treatment regimens, indicating a more advanced disease state that has become resistant to several standard therapeutic approaches.

Antihistamines Associated With Bladder Cancer Survival, Progression Improvements

March 13th 2025, 9:00pm

By Alex Biese

Article

Antihistamines are associated with improvement for patients with metastatic urothelial carcinoma receiving Tecentriq.

Dr. Kevin Kalinsky Covers Targeted Therapy in HER2– Breast Cancer

March 13th 2025, 7:00pm

By Dr. Kevin Kalinsky

Video

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, HER2-negative breast cancer.

Trusting My Stage 4 Breast Cancer Body

March 13th 2025, 5:00pm

By Martha Carlson

Article

Practicing consistency has made a difference for me while living with stage 4 breast cancer.

ctDNA Testing May Offer Patients With RCC ‘Peace of Mind’

March 13th 2025, 4:00pm

By Dr. Alan Tan

Video

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell carcinoma.

First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer

March 13th 2025, 3:00pm

By Spencer Feldman

Article

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant Bacillus Calmette-Guérin in the U.S.

Xtandi and Talzenna Therapy Shows Responses in Advanced Prostate Cancer

March 13th 2025, 1:00pm

By Dr. Chandler Park

Video

Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in terms of prostate cancer therapy.

Tedopi Cancer Vaccine Meets Trial End Point For Pancreatic Cancer

March 12th 2025, 9:00pm

By Ryan Scott

Article

The phase 2 TEDOPaM trial evaluating patients with advanced or metastatic pancreatic ductal adenocarcinoma met its primary end point.

Discussing the Mission of CURE With Our Former and New Editors-In-Chief

March 12th 2025, 7:00pm

By Dr. Joshua K. Sabari

Video

Our longtime editor-in-chief offers advice to his successor while discussing the news and education CURE magazine provides for patients with cancer, families and caregivers.

Four Things to Remember When Both Spouses Have Cancer

March 12th 2025, 5:00pm

By Chester Freeman

Article

When my spouse and I both faced cancer, maintaining a positive attitude, seeking support, listening empathetically and managing stress helped us through it.

First Patients Enrolled in Trial on Anti-HER2 Therapy in HER2+ Breast Cancer

March 12th 2025, 4:00pm

By Spencer Feldman

Article

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using circulating tumor DNA.

Targeted Axillary Dissection Offers a Precise Option in Breast Cancer

March 12th 2025, 3:00pm

By Dr. Kandace P. McGuire

Video

Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment.